TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18817348
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy
Study: 31179505
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear with heavy force (500 g)
Study: 31179505
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear with light force (300 g)
Study: 17562336
Drug: GnRH agonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 600 IU/day (n = 72)
Study: 17562336
Drug: GnRH agonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH agonist, low‐dose GnRH antagonist, and estradiol valerate followed by recombinant FSH, 750 IU/day (n = 65)
Study: 12404072
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hydrocodone/1.5 mg homatropine
Study: 12404072
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocodone/3 mg homatropine
Study: 12404072
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg hydrocodone/6 mg homatropine
Study: 12955305
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg morphine
Study: 9700978
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lorazepam
Study: 10705173
Drug: Teprenone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone 1.5 g/day for 8 weeks (PHG(+)‐t)
Study: 9552427
Drug: Slow-dissolving formulation
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-dissolving formulation
Study: 9552427
Drug: Medium-dissolving formulation
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dissolving formulation
Study: 9552427
Drug: Fast-dissolving formulation
Normalized name: melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fast-dissolving formulation
Study: 20649056
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg intravenously every 8 h
Study: 20649056
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg intravenously every 12 h
Study: 16934148
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics via the respiratory tract (gentamicin, polymyxins, tobramycin, ceftazidime)
Study: 1597846
Drug: DTZ SR/HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTZ SR/HCTZ (60/6.25 mg)
Study: 1597846
Drug: DTZ SR/HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTZ SR/HCTZ (90/6.25 mg)
Study: 1597846
Drug: HCTZ (6.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ (6.25, 6.25, 12.5 mg twice daily)
Study: 29153273
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (8 sessions)
Study: 26869076
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Suicide Prevention (CBSP) therapy
Study: 17909305
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy for 12 weeks followed by medroxyprogesterone acetate for 2 weeks
Study: 15516532
Drug: Sildenafil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (3 x 40 mg/day for 6 days)
Study: 9459371
Drug: Low-C diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-C diet (50 mg ascorbic acid/d)
Study: 9459371
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ascorbic acid/d (high-C diet)
Study: 7629982
Drug: Azithromycin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1.0 g as a single oral dose)
Study: 7629982
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg taken orally twice daily for 7 days)
Study: 2775615
Drug: Levodopa (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (50 mg) administered intravenously
Study: 2775615
Drug: Levodopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (250 mg) administered orally
Study: 2775615
Drug: Levodopa (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (50 mg) administered intravenously in the presence of carbidopa
Study: 30066465
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 mL bupivacaine 0.5% + 2 mL normal saline)
Study: 24715230
Drug: Subconjunctival and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival and/or intrastromal injections of 5 mg/0.2 ml Bevacizumab (3 injections)
Study: 24715230
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Bevacizumab injections)
Study: 21777886
Drug: Zotarolimus-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotarolimus-eluting stents with prolonged drug release (ZES-SR)
Study: 16454147
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (identical to treatment)
Study: 20089774
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment and placebo groups
Study: 27355400
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) gel
Study: 11932266
Drug: Dihydrotestosterone (DHT)
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (DHT) gel
Study: 10808696
Drug: Continuous hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous hormonal replacement therapy (HRT) with conjugated equine estrogen 0.625 mg/day and medroxyprogesterone acetate 2.5 mg/day for 21.3 +/- 9.5 months.
Study: 10808696
Drug: No hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormonal replacement therapy (Control group).
Study: 1599726
Drug: Two-visit intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit intervention group (risk assessment, support, cessation date setting, self-help literature, nicotine gum prescription)
Study: 4060998
Drug: Intramuscular opiates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular opiates post-operatively
Study: 3933262
Drug: Intramuscular group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular group
Study: 27881624
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy self-help intervention
Study: 16495243
Drug: Telavancin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin at 10 mg/kg intravenously every 24 h
Study: 16495243
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (antistaphylococcal penicillin at 2 g q6h or vancomycin at 1 g q12h)
Study: 15535882
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (patient education and exercise therapy)
Study: 3331041
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg b.i.d. (suspended in saline)
Study: 3331041
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg t.i.d. (suspended in saline)
Study: 3331041
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg b.i.d. (suspended in 1% lidocaine)
Study: 23093347
Drug: Teriparatide (28.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (28.2 or 56.5 μg injection)
Study: 17257460
Drug: Modafinil (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100-400 mg, administered once daily or as a divided dose)
Study: 9589355
Drug: Indole-3-carbinol (I3C)
DrugBank: Indole-3-carbinol (DB12881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indole-3-carbinol (I3C) 300 mg and 400 mg high-dose (HD)
Study: 9589355
Drug: Indole-3-carbinol (I3C)
DrugBank: Indole-3-carbinol (DB12881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indole-3-carbinol (I3C) 50 mg, 100 mg, 200 mg low-dose (LD)
Study: 15735366
Drug: High-genistein isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-genistein isoflavone extract (HGI, 150 mg/day)
Study: 2096041
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (Opium and Raphanus)
Study: 29412008
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: unenhanced CT with 100 kVp, 200 mA and contrast-enhanced CT with spectral CT mode using low dose protocols.
Study: 29412008
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: average radiation dose of 6.18 mSv.
Study: 18849625
Drug: 3-ml volume
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-ml volume of anesthetic solution
Study: 18849625
Drug: 5-ml volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ml volume of anesthetic solution
Study: 18849625
Drug: 7-ml volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-ml volume of anesthetic solution
Study: 9690694
Drug: Oral mCPP
Normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mCPP (0.5 mg/kg)
Study: 7578657
Drug: Intravenous mCPP
Normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mCPP (0.1 mg/kg over 20 min)
Study: 2267922
Drug: Hydrocortisone and
Normalized name: hydrocortisone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone and oral prednisolone for 5 days
Study: 26197184
Drug: H7N9 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N9 vaccine with MF59 adjuvant (15 µg hemagglutinin)
Study: 21368590
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine in HIV-infected pregnant women
Study: 21368590
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine in uninfected pregnant women
Study: 11535325
Drug: Zanamivir 20
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir 20 mg daily for 14 days
Study: 3058133
Drug: Muroctasin (MDP-Lys(L18))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muroctasin (MDP-Lys(L18)) at a dose of 200 micrograms, administered subcutaneously starting on day 4 after chemotherapy for 10 days
Study: 3058133
Drug: Control cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycle (standard chemotherapy protocol)
Study: 11598429
Drug: Cognitive-Behavioural Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioural Therapy (CBT)
Study: 28086934
Drug: Real electroacupuncture/moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real electroacupuncture/moxibustion treatments
Study: 28086934
Drug: Sham electroacupuncture/moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroacupuncture/moxibustion treatments
Study: 26094857
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist exenatide
Study: 10357429
Drug: 24% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% sucrose solution
Study: 10922432
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist therapy (diltiazem and verapamil)
Study: 1531673
Drug: Cl2MDP (2‐dichloromethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cl2MDP (2‐dichloromethylene bisphosphonate), 600 mg in 500 mL of normal saline
Study: 1531673
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mL of normal saline)
Study: 30665438
Drug: Integral movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Study: 30665438
Drug: Conventional local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional local movement therapy, 20 supervised sessions over 10 weeks, twice per week, approximately 1 hour per session.
Study: 19539384
Drug: allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: allopurinol 300 mg daily
Study: 15848559
Drug: Modified release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release tacrolimus (MR tacrolimus) once daily (qD)
Study: 15848559
Drug: Prograf twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prograf twice a day
Study: 8045844
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg/day)
Study: 2808215
Drug: Meropenem 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 0.25 g
Study: 2808215
Drug: Meropenem 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 0.5 g
Study: 2808215
Drug: Meropenem 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1.0 g
Study: 7013721
Drug: Oral mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mexiletine (200 mg 4 times daily)
Study: 30969203
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia
Study: 17876852
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide spray (1-2 sprays, maximum of 4 times per day)
Study: 17876852
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide spray
Study: 7740443
Drug: Dermatan sulphate
Normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulphate 300 mg twice daily
Study: 7740443
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic agents
Study: 25771840
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of placebo (olive oil)
Study: 23534988
Drug: Nanoparticle albumin-bound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) administered every 3 weeks (q3w)
Study: 20666686
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (500 mg daily, 4 consecutive days per month for 3 consecutive months)
Study: 19187076
Drug: AVE5026 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE5026 (5, 10, 20, 40, or 60 mg)
Study: 19187076
Drug: AVE5026 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE5026 (60 mg)
Study: 20458441
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg
Study: 1557967
Drug: fucithalmic drops
Normalized name: Fucithalmic
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fucithalmic drops twice daily
Study: 1557967
Drug: chloramphenicol (chlormycetin)
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chloramphenicol (chlormycetin) ointment twice daily
Study: 30218626
Drug: rasagiline 0.5
Normalized name: rasagiline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 0.5 mg
Study: 30218626
Drug: rasagiline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 1.0 mg
Study: 30218626
Drug: rasagiline 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 2.0 mg
Study: 30218626
Drug: rasagiline 0.5
Normalized name: rasagiline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline 0.5 mg (multiple administration)
Study: 28419317
Drug: High-Frequency Lanreotide
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-Frequency Lanreotide Autogel (120 mg/21 days)
Study: 28419317
Drug: High-Dose Lanreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Lanreotide Autogel (180 mg/28 days)
Study: 26510186
Drug: Low glucose
Normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glucose degradation product (GDP) solution
Study: 26510186
Drug: Conventional solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional solutions
Study: 21591985
Drug: NUTRIOSE(®) supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE(®) supplementation (17 g twice daily for 12 weeks)
Study: 17075115
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by 6 months of systemic adjuvant chemotherapy with fluorouracil and folinic acid
Study: 10326742
Drug: Dirithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (500 mg once daily for 5 days)
Study: 9950107
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once daily for 3 days)
Study: 8601548
Drug: Divalproex 20
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex 20 mg/kg/day
Study: 28605827
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral naltrexone plus a 30-day prescription
Study: 21895923
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine followed by PCA (Group P)
Study: 21895923
Drug: DO(2) I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: DO(2) I < 400 ml/min/m(2)
Study: 21895923
Drug: DO(2) I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: DO(2) I > 400 ml/min/m(2)
Study: 19255176
Drug: Initial infiltration
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus repeated infiltration of the same anesthetic 30 minutes later
Study: 19255176
Drug: Initial infiltration
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus mock repeated infiltration 30 minutes later
Study: 12172084
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy
Study: 16870008
Drug: Fish oil/5‐MTHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil/5‐MTHF treatment
Study: 12771974
Drug: Chitosan (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (1.2 g per day)
Study: 6437842
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg) with acarbose (3 X 100 mg daily)
Study: 27405061
Drug: 200-mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg group (50-mg intravenous bolus every 6 h during 7 days)
Study: 27405061
Drug: 300-mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg group (100-mg initial bolus followed by continuous infusion of 300 mg daily for 5 days)
Study: 27405061
Drug: 300-mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg group
Study: 27405061
Drug: 200-mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg group
Study: 23225445
Drug: Menatetrenone (MNT)
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (MNT) 45 mg daily
Study: 16301236
Drug: MgSO4 30
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 30 mg/kg
Study: 2719894
Drug: Amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150 mg daily for 13 days)
Study: 2719894
Drug: Femoxetine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine (600 mg daily for 13 days)
Study: 28211816
Drug: Levodopa-carbidopa intestinal
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa intestinal gel (LCIG) infusion
Study: 28211816
Drug: Immediate-release oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oral levodopa-carbidopa (LC-oral) treatment
Study: 23237136
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg/d
Study: 24913197
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg/d
Study: 19371823
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy beyond 6 months after index PCI
Study: 19371823
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of aspirin
Study: 11521725
Drug: trastuzumab (single-agent)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab (single-agent)
Study: 11521725
Drug: trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab plus paclitaxel (weekly)
Study: 11521725
Drug: aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: aromatase inhibitor ± trastuzumab
Study: 17050503
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan
Study: 2957859
Drug: Other infusion
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other infusion solutions
Study: 30634208
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XFC) 0.5 g/pill, 3 pills each time, 3 times per day for 90 days
Study: 19757017
Drug: 0.1% UC781
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% UC781 gel
Study: 10363611
Drug: Prednisolone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (2 x 250 mg)